Article

Loteprednol, azelastine provide potent arsenal for acute, chronic allergic conjunctivitis

Loteprednol etabonate 0.2% (Alrex, Bausch & Lomb) and azelastine hydrochloride 0.05% (Optivar, Muro) are both valuable options for the management of seasonal and perennial allergic conjunctivitis, said Charles Slonim, MD.

Related Videos
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
Related Content
FDA accepts new drug application for low-dose atropine from Sydnexis
March 11th 2025

FDA accepts new drug application for low-dose atropine from Sydnexis

ROP: Treating and preventing blindness in preterm babies
October 18th 2021

ROP: Treating and preventing blindness in preterm babies

AI and eye tracking: Technological companions to assess amblyopia in pediatric patients
March 3rd 2025

AI and eye tracking: Technological companions to assess amblyopia in pediatric patients

Managing a changing landscape of IRD pediatric cases
May 10th 2021

Managing a changing landscape of IRD pediatric cases

Study highlights strong parental cooperation in preschool vision screening
February 14th 2025

Study highlights strong parental cooperation in preschool vision screening

Vyluma announces NMPA of China accepts drug application of NVK002 (low-dose atropine 0.01%) for myopia progression in children
January 30th 2025

Vyluma announces NMPA of China accepts drug application of NVK002 (low-dose atropine 0.01%) for myopia progression in children

© 2025 MJH Life Sciences

All rights reserved.